Causes and treatment of oedema in patients with heart failure

Abstract

Oedema is one of the fundamental features of heart failure, but the pathophysiology of oedema varies. Patients present along a spectrum ranging from acute pulmonary oedema to gross fluid retention and peripheral oedema (anasarca). In patients with pure pulmonary oedema, the problem is one of acute haemodynamic derangement; the patient does not have excess fluid, but pulmonary venous pressure rises such that the rate of fluid transudation into the interstitium of the lung exceeds the capacity of the pulmonary lymphatics to drain away the fluid. Conversely, in patients with peripheral oedema, the problem is one of fluid retention. Understanding the causes of oedema will enable straightforward, correct management of the condition. For patients with acute pulmonary oedema, vasodilatation is important to reduce cardiac filling pressures. For patients with fluid retention, removing the fluid, using either diuretics or mechanical means, is the most important consideration.

Key Points

  • Oedema is one of the fundamental features of heart failure

  • Clinical trial data to guide best practice in managing cardiac oedema are lacking

  • Acute pulmonary oedema is characterized by accumulation of fluid in the air spaces, not by fluid overload

  • Acute pulmonary oedema is best treated as a haemodynamic problem using vasodilators

  • Peripheral oedema is characterized by an excess of total body water

  • Peripheral oedema is best treated by removing fluid, either with diuretics or mechanically

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: The Frank–Starling law of the heart.
Figure 2: The correlation between increasing left atrial pressure and the rate of development of pulmonary oedema.
Figure 3: X-ray of the chest of a patient presenting with acute pulmonary oedema.
Figure 4: Schematic representation of possible routes through which vasodilators exert their action.
Figure 5: The right thigh of a patient presenting with fluid retention and pitting oedema.
Figure 6: Pattern of weight loss in a patient presenting with peripheral oedema.
Figure 7: Time course of serum sodium level changes in a patient presenting with oedematous heart failure.

References

  1. 1

    Hospital Episode Statistics. HES online [online], (2012).

  2. 2

    Cleland, J. G. et al. The national heart failure audit for England and Wales 2008–2009 Heart 97, 876–86 (2011).

  3. 3

    National Heart Failure Audit 2010. The NHS Information Centre [online], (2012).

  4. 4

    Michalsen, A., König, G. & Thimme, W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 80, 437–441 (1998).

  5. 5

    Fonarow, G. C. et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch. Intern. Med. 168, 847–854 (2008).

  6. 6

    Roguin, A. et al. Long-term prognosis of acute pulmonary oedema--an ominous outcome. Eur. J. Heart Fail. 2, 137–144 (2000).

  7. 7

    Starling, E. H. On the absorption of fluids from the connective tissue spaces. J. Physiol. 19, 312–326 (1896).

  8. 8

    Erdmann, A. J. 3rd, Vaughan, T. R. Jr, Brigham, K. L., Woolverton, W. C. & Staub, N. C. Effect of increased vascular pressure on lung fluid balance in unanesthetized sheep. Circ. Res. 37, 271–284 (1975).

  9. 9

    Guyton, A. C. & Lindsey, A. W. Effect of elevated left atrial pressure and decreased plasma protein concentration on the development of pulmonary edema. Circ. Res. 7, 649–657 (1959).

  10. 10

    Figueras, J. & Weil, M. H. Blood volume prior to and following treatment of acute cardiogenic pulmonary edema. Circulation 57, 349–355 (1978).

  11. 11

    Cotter, G. et al. The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. Eur. J. Heart Fail. 5, 443–451 (2003).

  12. 12

    Pickering, T. G. et al. Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: treatment by angioplasty or surgical revascularisation. Lancet 2, 551–552 (1988).

  13. 13

    Lohmeier, T. E., Mizelle, H. L., Reinhart, G. A. & Montani, J. P. Influence of angiotensin on the early progression of heart failure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 278, R74–R86 (2000).

  14. 14

    Hall, J. E. et al. Mechanisms of escape from sodium retention during angiotensin II hypertension. Am. J. Physiol. 246, F627–F634 (1984).

  15. 15

    van Iperen, C. E., Giezen, J., Kramer, W. L. M., Lips, C. J. M. & Bartelink, A. K. Acute dyspnea resulting from pulmonary oedema as the first sign of a pheochromocytoma. Respiration 68, 323–326 (2001).

  16. 16

    Sartori, C., Allemann, Y. & Scherrer, U. Pathogenesis of pulmonary edema: learning from high-altitude pulmonary edema. Respir. Physiol. Neurobiol. 159, 338–349 (2007).

  17. 17

    Fein, A. et al. The value of edema fluid protein measurements in patients with pulmonary edema. Am. J. Med. 67, 32–38 (1979).

  18. 18

    Colombo, P. C., Onat, D. & Sabbah, H. N. Acute heart failure as “acute endothelitis”--Interaction of fluid overload and endothelial dysfunction. Eur. J. Heart Fail. 10, 170–175 (2008).

  19. 19

    Oldenburg, O. et al. Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and characteristics of 700 patients. Eur. J. Heart Fail. 9, 251–257 (2007).

  20. 20

    Fletcher, E. C. et al. Pulmonary edema develops after recurrent obstructive apneas. Am. J. Respir. Crit. Care Med. 160, 1688–1696 (1999).

  21. 21

    Kasai, T. et al. Relationship between sodium intake and sleep apnea in patients with heart failure. J. Am. Coll. Cardiol. 58, 1970–1974 (2011).

  22. 22

    Mackersie, R. C., Christensen, J. & Lewis, F. R. The role of pulmonary lymphatics in the clearance of hydrostatic pulmonary edema. J. Surg. Res. 43, 495–504 (1987).

  23. 23

    Tandon, H. D. & Kasturi, J. Pulmonary vascular changes associated with isolated mitral stenosis in India. Br. Heart J. 37, 26–36 (1975).

  24. 24

    Davies, S. W. et al. Reduced pulmonary microvascular permeability in severe chronic left heart failure. Am. Heart J. 124, 137–142 (1992).

  25. 25

    Huang, W. et al. Capillary filtration is reduced in lungs adapted to chronic heart failure: morphological and haemodynamic correlates. Cardiovasc. Res. 49, 207–217 (2001).

  26. 26

    Puri, S. et al. Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance. Circulation 91, 2769–2774 (1995).

  27. 27

    Parissis, J. T. et al. Acute pulmonary oedema: clinical characteristics, prognostic factors, and in-hospital management. Eur. J. Heart Fail. 12, 1193–1202 (2010).

  28. 28

    Zannad, F. et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. Eur. J. Heart Fail. 8, 697–705 (2006).

  29. 29

    Mebazaa, A. et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur. Heart J. 31, 832–841 (2010).

  30. 30

    Dickstein, K. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Eur. Heart J. 29, 2388–2442 (2008).

  31. 31

    Gossop, M., Keaney, F., Sharma, P. & Jackson, M. The unique role of diamorphine in British medical practice: a survey of general practitioners and hospital doctors. Eur. Addict.Res. 11, 76–82 (2005).

  32. 32

    McMurray, J. J. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 33, 1787–1847 (2012).

  33. 33

    Vismara, L. A., Leaman, D. M. & Zelis, R. The effects of morphine on venous tone in patients with acute pulmonary oedema. Circulation 54, 335–337 (1976).

  34. 34

    Grossmann, M., Abiose, A., Tangphao, O., Blaschke, T. F. & Hoffman, B. B. Morphine-induced venodilation in humans. Clin. Pharmacol. Ther. 60, 554–560 (1996).

  35. 35

    Feeney, C., Ani, C., Sharma, N. & Frohlich, T. Morphine-induced cardiogenic shock. Ann. Pharmacother. 45, e30 (2011).

  36. 36

    Sosnowski, M. A. Review article: lack of effect of opiates in the treatment of acute cardiogenic pulmonary oedema. Emerg. Med. Australas. 20, 384–390 (2008).

  37. 37

    Peacock, W. F. et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg. Med. J. 25, 205–209 (2008).

  38. 38

    Clark, A. L., Johnson, M. J. & Squire, I. Does home oxygen benefit people with chronic heart failure? BMJ 342, d234 (2011).

  39. 39

    British Thoracic Society Standards of Care Committee. Non-invasive ventilation in acute respiratory failure. Thorax 57, 192–211 (2002).

  40. 40

    Esteban, A., De Elió, F. J., Ancillo, P., Gómez-Acebo, E. & Cerdá, E. Continuous positive pressure ventilation in the management of eight cases of acute pulmonary oedema. Br. J. Anaesth. 45, 1070–1074 (1973).

  41. 41

    Simpson, P. M. & Bendall, J. C. Prehospital non-invasive ventilation for acute cardiogenic pulmonary oedema: an evidence-based review. Emerg. Med. J. 28, 609–612 (2011).

  42. 42

    Peter, J. V., Moran, J. L., Phillips-Hughes, J., Graham, P. & Bersten, A. D. Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis. Lancet 367, 1155–1163 (2006).

  43. 43

    Gray, A. et al. Noninvasive ventilation in acute cardiogenic pulmonary edema. N. Engl. J. Med. 359, 142–151 (2008).

  44. 44

    Dikshit, K. et al. Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N. Engl. J. Med. 288, 1087–1090 (1973).

  45. 45

    Larsen, F. F. Haemodynamic effects of high or low doses of furosemide in acute myocardial infarction. Eur. Heart J. 9, 125–131 (1988).

  46. 46

    Kiely, J., Kelly, D. T., Taylor, D. R. & Pitt, B. The role of furosemide in the treatment of left ventricular dysfunction associated with acute myocardial infarction. Circulation 48, 581–587 (1973).

  47. 47

    Holzer-Richling, N. et al. Randomized placebo controlled trial of furosemide on subjective perception of dyspnoea in patients with pulmonary oedema because of hypertensive crisis. Eur. J. Clin. Invest. 41, 627–634 (2011).

  48. 48

    Hayashi, S. Y. et al. Acute effects of low and high intravenous doses of furosemide on myocardial function in anuric haemodialysis patients: a tissue Doppler study. Nephrol. Dial. Transplant. 23, 1355–1361 (2008).

  49. 49

    Ikram, H., Chan, W., Espiner, E. A. & Nicholls, M. G. Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. Clin. Sci. 59, 443–449 (1980).

  50. 50

    Towers, K. A., Bardsley, K. A. & Macdonald, P. S. Nebulised frusemide for the symptomatic treatment of end-stage congestive heart failure. Med. J. Aust. 193, 555 (2010).

  51. 51

    Shimoyama, N. & Shimoyama, M. Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. J. Pain Symptom Manage. 23, 73–76 (2002).

  52. 52

    Newton, P. J., Davidson, P. M., Krum, H., Ollerton, R. & Macdonald, P. The acute haemodynamic effect of nebulised frusemide in stable, advanced heart failure. Heart Lung Circ. 21, 260–266 (2012).

  53. 53

    Adams, K. F. Jr et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart J. 149, 209–216 (2005).

  54. 54

    Franciosa, J. A. & Silverstein, S. R. Hemodynamic effects of nitroprusside and furosemide in left ventricular failure. Clin. Pharmacol. Ther. 32, 62–69 (1982).

  55. 55

    Nelson, G. I., Silke, B., Ahuja, R. C., Hussain, M. & Taylor, S. H. Haemodynamic advantages of isosorbide dinitrate over furosamide in acute heart failure following myocardial infarction. Lancet 1, 730–732 (1983).

  56. 56

    Beltrame, J. F. et al. Nitrate therapy is an alternative to furosemide/morphine therapy in the management of acute cardiogenic pulmonary edema. J. Card. Fail. 4, 271–279 (1998).

  57. 57

    Cotter, G. et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351, 389–393 (1998).

  58. 58

    Sharon, A. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J. Am. Coll. Cardiol. 36, 832–837 (2000).

  59. 59

    Hamilton, R. J., Carter, W. A. & Gallagher, E. J. Rapid improvement of acute pulmonary edema with sublingual captopril. Acad. Emerg. Med. 3, 205–212 (1996).

  60. 60

    Spieker, L. E. et al. Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators. J. Am. Coll. Cardiol. 35, 1745–1752 (2000).

  61. 61

    Kaluski, E. et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 41, 204–210 (2003).

  62. 62

    Teerlink, J. R., Massie, B. M., Cleland, J. G. F. & Tzivoni, D. for the RITZ-1 investigators. A double-blind, parallel-group, multicenter, placebo-controlled study to investigate the efficacy and safety of tezosentan in reducing symptoms in patients with acute decompensated heart failure [abstract]. Circulation 104, II–526 (2001).

  63. 63

    McMurray, J. J. et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298, 2009–2019 (2007).

  64. 64

    Kohan, D. E., Cleland, J. G., Rubin, L. J., Theodorescu, D. & Barton, M. Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve? Life Sci. 91, 528–539 (2012).

  65. 65

    Coletta, A., Thackray, S. & Nikitin, N., Cleland, J. G. Clinical trials update: highlights of the scientific sessions of The American College of Cardiology LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL. Eur. J. Heart Fail. 4, 381–388 (2002).

  66. 66

    Mills, R. M. et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J. Am. Coll. Cardiol. 34, 155–162 (1999).

  67. 67

    Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287, 1531–1540 (2002).

  68. 68

    O'Connor, C. M. et al. Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med. 365, 32–43 (2011).

  69. 69

    Ando, S., Imaizumi, T., Harada, S., Hirooka, Y. & Takeshita, A. Atrial natriuretic peptide increases human capillary filtration and venous distensibility. J. Hypertens. 10, 451–457 (1992).

  70. 70

    Chen, W. et al. Atrial natriuretic peptide enhances microvascular albumin permeability by the caveolae-mediated transcellular pathway. Cardiovasc. Res. 93, 141–151 (2012).

  71. 71

    Debrah, D. O., Conrad, K. P., Jeyabalan, A., Danielson, L. A. & Shroff, S. G. Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats. Hypertension 46, 745–750 (2005).

  72. 72

    Teerlink, J. R. et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373, 1429–1439 (2009).

  73. 73

    Teerlink, J. R. et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(12)61855-8.

  74. 74

    US National Library of Medicine. ClinicalTrials.gov [online], (2012).

  75. 75

    Sartori, C., Matthay, M. A. & Scherrer, U. Transepithelial sodium and water transport in the lung. Major player and novel therapeutic target in pulmonary edema. Adv. Exp. Med. Biol. 502, 315–338 (2001).

  76. 76

    Matthay, M. A., Folkesson, H. G. & Clerici, C. Lung epithelial fluid transport and the resolution of pulmonary edema. Physiol. Rev. 82, 569–600 (2002).

  77. 77

    Mutlu, G. M. et al. Upregulation of alveolar epithelial active Na+ transport is dependent on beta2-adrenergic receptor signaling. Circ. Res. 94, 1091–1100 (2004).

  78. 78

    Mutlu, G. M. & Factor, P. Alveolar epithelial beta2-adrenergic receptors. Am. J. Respir. Cell. Mol. Biol. 38, 127–134 (2008).

  79. 79

    Maak, C. A., Tabas, J. A. & McClintock, D. E. Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure? J. Emerg. Med. 40, 135–145 (2011).

  80. 80

    Thorneloe, K. S. et al. An orally active TRPV4 channel blocker prevents and resolves pulmonary edema in heart failure. Sci. Transl. Med. 4, 159ra148 (2012).

  81. 81

    Gheorghiade, M. et al. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur. J. Heart Fail. 14, 1056–1066 (2012).

  82. 82

    Benz, K. et al. Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage. Kidney Blood Press. Res. 30, 224–233 (2007).

  83. 83

    Jones, E. S., Kemp-Harper, B., Stasch, J. P., Schmidt, H. & Widdop, R. E. Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation/activation of sGC without hypotension. BMC Pharmacol. 9 (Suppl. 1), P29 (2009).

  84. 84

    Capomolla, S. et al. Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome. Eur. J. Heart Fail. 3, 601–610 (2001).

  85. 85

    Thackray, S., Easthaugh, J., Freemantle, N. & Cleland, J. G. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur. J. Heart Fail. 4, 515–529 (2002).

  86. 86

    Follath, F. et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360, 196–202 (2002).

  87. 87

    Mebazaa, A. et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297, 1883–1891 (2007).

  88. 88

    Landoni, G. et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit. Care Med. 40, 634–646 (2012).

  89. 89

    Bragadeesh, T. K., Mathur, G., Clark, A. L. & Cleland, J. G. Novel cardiac myosin activators for acute heart failure. Expert Opin. Investig. Drugs 16, 1541–1548 (2007).

  90. 90

    Cleland, J. G. et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 378, 676–683 (2011).

  91. 91

    US National Library of Medicine. ClinicalTrials.gov [online], (2012).

  92. 92

    Gheorghiade, M. et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J. Am. Coll. Cardiol. 51, 2276–2285 (2008).

  93. 93

    Shah, S. J. et al. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. Am. Heart J. 157, 1035–1041 (2009).

  94. 94

    Thiele, H. et al. Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Am. Heart J. 163, 938–945 (2012).

  95. 95

    Thiele, H. et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N. Engl. J. Med. 163, 938–945 (2012).

  96. 96

    Engström, A. E. et al. The Impella 2.5 and 5.0 devices for ST-elevation myocardial infarction patients presenting with severe and profound cardiogenic shock: the Academic Medical Center intensive care unit experience. Crit. Care Med. 39, 2072–2079 (2011).

  97. 97

    Stack, R. S., Stack, R. K., Morris, K. G., Bauman, R. P. & Shadoff, N. Temporary balloon occlusion of the inferior vena cava for immediate reversal of acute pulmonary edema. Am. J. Cardiol. 57, 886–887 (1986).

  98. 98

    Warner, G. F., Dobson, E. L., Rodgers, C. E., Johnston, M. E. & Pace, N. The measurement of total “sodium space” and total body sodium in normal individuals and in patients with cardiac edema. Circulation 5, 915–919 (1952).

  99. 99

    Cleland, J. G., Dargie, H. J., Robertson, I., Robertson, J. I. & East, B. W. Total body electrolyte composition in patients with heart failure: a comparison with normal subjects and patients with untreated hypertension. Br. Heart J. 58, 230–238 (1987).

  100. 100

    Anand, I. S. et al. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 80, 299–305 (1989).

  101. 101

    Harris, P. Evolution and the cardiac patient. Cardiovasc. Res. 17, 313–319, 373–378, 437–345 (1983).

  102. 102

    Franklin, S. S., et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 96, 308–315 (1997).

  103. 103

    Merrill, A. J. Edema and decreased renal blood flow in patients with chronic congestive heart failure: evidence of “forward failure” as primary cause of edema. J. Clin. Invest. 25, 389–400 (1946).

  104. 104

    Skinner, S. L., McCubbin, J. W. & Page, I. H. Control of renin secretion. Circ. Res. 15, 64–76 (1964).

  105. 105

    Farhi, E. R., Cant, J. R. & Barger, A. C. Interactions between intrarenal epinephrine receptors and the renal baroreceptor in the control of PRA in conscious dogs. Circ. Res. 50, 477–485 (1982).

  106. 106

    Knepper, M. A. Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am. J. Physiol. Renal Physiol. 41, F3–F12 (1997).

  107. 107

    Bonjour, J. P. & Malvin, R. L. Stimulation of ADH release by the renin-angiotensin system. Am. J. Physiol. 218, 1555–1559 (1970).

  108. 108

    Szatalowicz, V. L. et al. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N. Engl. J. Med. 305, 263–266 (1981).

  109. 109

    Francis, G. S. et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82, 1724–1729.

  110. 110

    Robertson, G. L. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am. J. Med. 119 (Suppl. 1), S36–S42 (2006).

  111. 111

    Nordgren, L. & Sörensen, S. Symptoms experienced in the last six months of life in patients with end-stage heart failure. Eur. J. Cardiovasc. Nurs. 2, 213–217 (2003).

  112. 112

    Falk, S., Wahn, A.-K. & Lidell, E. Keeping the maintenance of daily life in spite of chronic heart failure. A qualitative study. Eur. J. Cardiovasc. Nurs. 6, 192–199 (2007).

  113. 113

    Waldréus, N., Sjöstrand, F. & Hahn, R. G. Thirst in the elderly with and without heart failure. Arch. Gerontol. Geriatr. 53, 174–178 (2011).

  114. 114

    Farrell, M. J. et al. Effect of aging on regional cerebral blood flow responses associated with osmotic thirst and its satiation by water drinking: a PET study. Proc. Natl Acad. Sci. USA 105, 382–387 (2008).

  115. 115

    Ramsay, D. J., Rolls, B. J. & Wood, R. J. The relationship between elevated water intake and oedema associated with congestive cardiac failure in the dog. J. Physiol. 244, 303–312 (1975).

  116. 116

    Johnson, A. K., Mann, J. F., Rascher, W., Johnson, J. K. & Ganten, D. Plasma angiotensin II concentrations and experimentally induced thirst. Am. J. Physiol. 240, R229–R234 (1981).

  117. 117

    Szczepanska-Sadowska, E., Sobocinska, J. & Sadowski, B. Central dipsogenic effect of vasopressin. Am. J. Physiol. 242, R372–R379 (1982).

  118. 118

    Travers, B. et al. Fluid restriction in the management of decompensated heart failure: no impact on time to clinical stability. J. Card. Fail. 13, 128–132 (2007).

  119. 119

    Holst, M., Strömberg, A., Lindholm, M. & Willenheimer, R. Liberal versus restricted fluid prescription in stabilised patients with chronic heart failure: result of a randomised cross-over study of the effects on health-related quality of life, physical capacity, thirst and morbidity. Scand. Cardiovasc. J. 42, 316–322 (2008).

  120. 120

    Abildgaard, U. et al. Bed rest and increased diuretic treatment in chronic congestive heart failure. Eur. Heart J. 6, 1040–1046 (1985).

  121. 121

    McDonald, C. D., Burch, G. E. & Walsh, J. J. Prolonged bed rest in the treatment of idiopathic cardiomyopathy. Am. J. Med. 52, 41–50 (1972).

  122. 122

    Flapan, A. D. et al. The influence of posture on the response to loop diuretics in patients with chronic cardiac failure is reduced by angiotensin converting enzyme inhibition. Eur. J. Clin. Pharmacol. 42, 581–585 (1992).

  123. 123

    Miller, W. L., Bailey, K. R., Weston, S. A., Burnett, J. C. Jr & Rodeheffer, R. J. Hemodynamic and plasma atrial natriuretic peptide responses to acute digitalis therapy in patients with normal and impaired left ventricular function. Eur. J. Heart Fail. 4, 63–72 (2002).

  124. 124

    CLOTS (Clots in Legs Or sTockings after Stroke) Trial Collaboration. Thigh-length versus below-knee stockings for deep venous thrombosis prophylaxis after stroke: a randomized trial. Ann. Intern. Med. 153, 553–562 (2010).

  125. 125

    de Silva, R. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur. Heart J. 27, 569–581 (2006).

  126. 126

    Maxwell, A. P., Ong, H. Y. & Nicholls, D. P. Influence of progressive renal dysfunction in chronic heart failure. Eur. J. Heart Fail. 4, 125–130 (2002).

  127. 127

    Cleland, J. G. et al. Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. Heart Fail. Rev. 17, 133–149 (2012).

  128. 128

    Harjola, V. P. et al. Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. Eur. J. Heart Fail. 12, 239–248 (2010).

  129. 129

    Elkayam, U. et al. Renal circulatory effects of adenosine in patients with chronic heart failure. J. Am. Coll. Cardiol. 32, 211–215 (1998).

  130. 130

    Massie, B. M. et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N. Engl. J. Med. 363, 1419–1428 (2010).

  131. 131

    Dormans, T. P., Gerlag, P. G., Russel, F. G. & Smits, P. Combination diuretic therapy in severe congestive heart failure. Drugs 2, 165–172 (1998).

  132. 132

    Brater, D. C. Pharmacology of diuretics. Am. J. Med. Sci. 319, 38–50 (2000).

  133. 133

    Pothuizen, L. M. & Chada, D. R. Treatment of congestive cardiac failure in elderly patients: randomised study of hydrochlorothiazide and slow release furosemide. Curr. Ther. Res. 32, 513–519 (1982).

  134. 134

    Vermeulen, A. & Chada, D. R. Slow-release furosemide and hydrochlorothiazide in congestive cardiac failure: A controlled trial. J. Clin. Pharmacol. 22, 513–519 (1982).

  135. 135

    Krause, U., Zielke, A., Schmidt-Gayk, H., Ehrenthal, W. & Beyer, J. Direct tubular effect on calcium retention by hydrochlorothiazide. J. Endocrinol. Invest. 12, 531–535 (1989).

  136. 136

    Solomon, D. H., Mogun, H., Garneau, K. & Fischer, M. A. Risk of fractures in older adults using antihypertensive medications. J. Bone Miner. Res. 26, 1561–1567 (2011).

  137. 137

    Dargie, H. J., Allison, M. E., Kennedy, A. C. & Gray, M. H. High dose metolazone in chronic renal failure. Br. Med. J. 4, 196–198 (1972).

  138. 138

    Kohvakka, A. Maintenance of potassium balance during long-term diuretic therapy in chronic heart failure patients with thiazide induced hypokalemia: comparison of potassium supplementation with potassium chloride and potassium-sparing agents, amiloride and triamterene. Int. J. Clin. Pharmacol. Ther. Toxicol. 26, 273–277 (1988).

  139. 139

    Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709–717 (1999).

  140. 140

    Zannad, F. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11–21 (2011).

  141. 141

    Stewart, J. H. & Edwards, K. D. G. Clinical comparison of frusemide with bendrofluazide, mersalyl and ethacrynic acid. Br. Med. J. 2, 1277–1281 (1965).

  142. 142

    Kaissling, B. & Stanton, B. A. Adaptation of distal tubule and collecting duct to increased sodium delivery: I Ultrastructure. Am. J. Physiol. 255, F1256–F1275 (1988).

  143. 143

    Stanton, B. A. & Kaissling, B. Adaptation of distal tubule and collecting duct to increased Na delivery. II. Na and K transport. Am. J. Physiol. 255, 1269–1275 (1988).

  144. 144

    Murray, M. D., Haag, K. M., Black, P. K., Hall, S. D. & Brater, D. C. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacother. 17, 98–106 (1997).

  145. 145

    Vasko, M. R., Cartwright, D. B., Knochel, J. P. Nixon, J. V. & Brater, D. C. Furosemide absorption altered in decompensated congestive heart failure. Ann. Intern. Med. 102, 314–318 (1985).

  146. 146

    van Meyel, J. J. et al. Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. J. Intern. Med. 235, 329–334 (1994).

  147. 147

    Dormans, T. P. et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus versus continuous infusion. J. Am. Coll. Cardiol. 28, 376–382 (1996).

  148. 148

    Lahav, M., Regev, A., Ra'anani, P. & Theodor, E. Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest 102, 725–731 (1992).

  149. 149

    Pivac, N. et al. Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure. Int. J. Clin. Pharmacol. Res. 18, 121–128 (1998).

  150. 150

    Paterna, S. et al. Effects of high dose furosemide and small volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur. J. Heart Fail. 2, 305–313 (2000).

  151. 151

    Rudy, D. W., Voelker, J. R., Greene, P. K., Esparza, F. A. & Brater, D. C. Loop diuretics for renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann. Intern. Med. 115, 360–366 (1991).

  152. 152

    Felker, G. M. et al. Diuretic strategies in patients with acute decompensated heart failure. N. Engl. J. Med. 364, 797–805 (2011).

  153. 153

    Sigured, B., Olesen, K. H. & Wennevold, A. The supra-additive natriuretic effect of addition of bendroflumethiazide and bumetanide in congestive heart failure. Am. Heart J. 89, 163–170 (1975).

  154. 154

    Channer, K. S., McLean, K. A., Lawson-Matthew, P. & Richardson, M. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br. Heart J. 71, 146–150 (1994).

  155. 155

    Bartoli, E. et al. Blunting of furosemide diuresis by aspirin in man. J. Clin. Pharmacol. 20, 452–458 (1980).

  156. 156

    Jondeau, G. et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur. Heart J. 30, 2186–2192 (2009).

  157. 157

    Metra, M. et al. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur. J. Heart Fail. 9, 901–909 (2007).

  158. 158

    [No authors listed] The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N. Engl. J. Med. 336, 525–533 (1997).

  159. 159

    Gavey, C. J. & Parkinson, J. Digitalis in heart failure with normal rhythm. Br. Heart J. 1, 27–44 (1939).

  160. 160

    Ahmed, A. et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur. Heart J. 27, 178–186 (2006).

  161. 161

    Kolff, W. J. & Leonards, J. R. Reduction of otherwise intractable edema by dialysis or filtration. Cleveland Clin. Q. 21, 61–71 (1954).

  162. 162

    Marenzi, G. et al. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J. Am. Coll. Cardiol. 38, 963–968 (2001).

  163. 163

    Bart, B. A. et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J. Am. Coll. Cardiol. 46, 2043–2046 (2005).

  164. 164

    Libetta, C. et al. Intermittent haemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines. Nephrol. Dial. Transplant. 22, 2013–2019 (2007).

  165. 165

    Costanzo, M. R. et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol. 49, 675–683 (Erratum. J. Am. Coll. Cardiol. 49, 1136 [2007]).

  166. 166

    Agostoni, P. et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am. J. Med. 96, 191–199 (1994).

  167. 167

    Ali, S. S. et al. Loop diuretics can cause clinical natriuretic failure: a prescription for volume expansion. Congest. Heart Fail. 15, 1–4 (2009).

  168. 168

    Costanzo, M. R., Saltzberg, M., O'Sullivan, J. & Sobotka, P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J. Am. Coll. Cardiol. 46, 2047–2051 (2005).

  169. 169

    Patarroyo, M. et al. Cardiorenal outcomes after slow continuous ultrafiltration therapy in refractory patients with advanced decompensated heart failure. J. Am. Coll. Cardiol. 60, 1906–1912 (2012).

  170. 170

    Bart, B. A. et al. Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. J. Card. Fail. 18, 176–182 (2012).

  171. 171

    Bart, B. A. et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N. Engl. J. Med. 367, 2296–2304 (2012).

  172. 172

    Lee, W. H. & Packer, M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 73, 257–267 (1986).

  173. 173

    Francis, G. S. et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82, 1724–1729 (1990).

  174. 174

    Licata, G. et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am. Heart J. 145, 459–466 (2003).

  175. 175

    Paterna, S. et al. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J. Am. Coll. Cardiol. 45, 1997–2003 (2005).

  176. 176

    Paterna, S., Gaspare, P., Fasullo, S., Sarullo, F. M. & Di Pasquale, P. Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clin. Sci. (Lond.) 114, 221–230 (2008).

  177. 177

    Dinicolantonio, J. J., Pasquale, P. D., Taylor, R. S. & Hackam, D. G. Low sodium versus normal sodium diets in systolic heart failure: systematic review and meta-analysis. Heart http://dx.doi.org/10.1136/heartjnl-2012-302337.

  178. 178

    Packer, M., Medina, N. & Yushak, M. Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition. Ann. Intern. Med. 100, 782–789 (1984).

  179. 179

    Gheorghiade, M. et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107, 2690–2696 (2003).

  180. 180

    Konstam, M. A. et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297, 1319–1331 (2007).

  181. 181

    Cowburn, P. J., Patel, H., Jolliffe, R. E., Wald, R. W. & Parker, J. D. Cardiac resynchronization therapy: an option for inotrope-supported patients with end-stage heart failure? Eur. J. Heart Fail. 7, 215–217 (2005).

  182. 182

    Anker, S. D., Koehler, F. & Abraham, W. T. Telemedicine and remote management of patients with heart failure. Lancet 378, 731–739 (2011).

  183. 183

    Cleland, J. G. & Clark, A. L. Delivering the cumulative benefits of triple therapy to improve outcomes in heart failure: too many cooks will spoil the broth. J. Am. Coll. Cardiol. 42, 1234–1237 (2003).

  184. 184

    Shelton, R. J., Clark, A. L., Kaye, G. C. & Cleland, J. G. The atrial fibrillation paradox of heart failure. Congest. Heart Fail. 16, 3–9 (2010).

  185. 185

    Clark, A. L., Goode, K. & Cleland, J. G. The prevalence and incidence of left bundle branch block in ambulant patients with chronic heart failure. Eur. J. Heart Fail. 10, 696–702 (2008).

  186. 186

    QS9 Quality heart failure quality standard. National Institute for Health and Clinical Excellence [online], (2012).

  187. 187

    Voors, A. A. et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J. Am. Coll. Cardiol. 57, 1899–1907 (2011).

Download references

Author information

Both authors researched data for article, and made substantial contribution to discussion of content and to reviewing and editing of manuscript before submission. A. L. Clark wrote the article.

Correspondence to Andrew L. Clark.

Ethics declarations

Competing interests

A. L. Clark declares that he is on the advisory board for Novartis. J. G. F. Cleland declares that he has been a consultant for and received grants from Amgen and Novartis.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Clark, A., Cleland, J. Causes and treatment of oedema in patients with heart failure. Nat Rev Cardiol 10, 156–170 (2013). https://doi.org/10.1038/nrcardio.2012.191

Download citation

Further reading